Abstract
Ovarian cancer has a poor overall survival which is partly caused by resistance to drugs such as cisplatin. Resistance can be acquired as a result of changes to the tumour or due to altered interactions within the tumour microenvironment. Extracellular vesicles (EVs), small lipid-bound vesicles that are loaded with macromolecular cargo and released by cells, are emerging as mediators of communication in the tumour microenvironment. We previously showed that EVs mediate the bystander effect, a phenomenon in which stressed cells can communicate with neighbouring naïve cells leading to various effects including DNA damage; however, the role of EVs released following cisplatin treatment has not been tested. Here we show that treatment of cells with cisplatin led to the release of EVs that could induce invasion and increased resistance when taken up by bystander cells. This coincided with changes in p38 and JNK signalling, suggesting that these pathways may be involved in mediating the effects. We also show that EV uptake inhibitors could prevent this EV-mediated adaptive response and thus sensitise cells in vitro to the effects of cisplatin. Our results suggest that preventing pro-tumourigenic EV crosstalk during chemotherapy is a potential therapeutic target for improving outcome in ovarian cancer patients.
| Original language | English |
|---|---|
| Article number | 20170065 |
| Journal | Philosophical Transactions of the Royal Society of London B: Biological Sciences |
| Volume | 373 |
| Issue number | 1737 |
| DOIs | |
| Publication status | Published - 20 Nov 2017 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Cisplatin induces the release of extracellular vesicles from ovarian cancer cells that can induce invasiveness and drug resistance in bystander cells'. Together they form a unique fingerprint.Profiles
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver